Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Grande Delta Corporation currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner. The workload is contained within 1 distinct art unit. Practitioners should note that the presence of these factors defines the current prosecution progress for the portfolio. This volume of activity indicates the current scale of the company's engagement with the patent office. The Biotechnology & Pharmaceuticals sector often requires detailed technical review, and here that review is handled by the assigned personnel.
The busiest examiner assigned to the portfolio is JONES-FOSTER, ERICA NICOLE. This examiner is responsible for 1 busiest examiner pending office action, which accounts for the total pending actions currently facing the corporation. Because the data shows the involvement of 1 distinct examiner and 1 distinct art unit, the administrative requirements for managing these filings are restricted to these specific points. The 1 pending office action allows for a response directed to the examiner's concerns. Practitioners can focus their resources on the assigned official to advance the application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES-FOSTER, ERICA NICOLE | 1 | 50.0% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568728 | METHODS OF PROCESSING COLLAGEN FROM ANIMAL TISSUE | JONES-FOSTER, ERICA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568728 | METHODS OF PROCESSING COLLAGEN FROM ANIMAL TISSUE | JONES-FOSTER, ERICA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568728 | METHODS OF PROCESSING COLLAGEN FROM ANIMAL TISSUE | JONES-FOSTER, ERICA NICOLE | 1656 | §102§103 | Non-Final OA | — | Pending | Dec 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGrande Delta Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erica Nicole Jones-Foster has the most, with 1 of Grande Delta Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.